# Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

> **NCT01348009** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 63 (estimated)

## Conditions studied

- Gastric Carcinoma

## Interventions

- **DRUG:** Tesetaxel-capecitabine-cisplatin

## Key facts

- **NCT ID:** NCT01348009
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-05
- **Primary completion:** 2013-10
- **Final completion:** 2014-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348009, "Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01348009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*